Oral-ATO for TP53-mutated Myeloid Malignancies
Phase 2 Recruiting
30 enrolled
Arsenic Trioxide With MAPK Inhibitors and Chemotherapy for Stage 4/M Neuroblastoma
Phase 2 Recruiting
92 enrolled
Treatment Study for Children and Adolescents With Acute Promyelocytic Leukemia
Phase 2 Recruiting
89 enrolled
Arsenic Trioxide Combined With Chemotherapy for the Treatment of p53-mutated Pediatric Cancer
Phase 2 Recruiting
50 enrolled
S0535, Gemtuzumab and Combination Chemotherapy in Treating Patients With Previously Untreated Acute Promyelocytic Leukemia
Phase 2 Completed
78 enrolled 8 charts
Combined Tretinoin and Arsenic Trioxide for Patients With Newly Diagnosed Acute Promyelocytic Leukemia Followed by Risk-Adapted Postremission Therapy
Phase 2 Completed
17 enrolled 8 charts
Leukemia SPORE Phase II DAC Study for R/R and Elderly Acute AML and MDS
Phase 2 Completed
92 enrolled
Arsenic Trioxide in Refractory Solid Tumors With Rescuable p53 Mutation
Phase 2 Unknown
20 enrolled
Study of Arsenic Trioxide in Small Cell Lung Cancer
Phase 2 Completed
20 enrolled 8 charts
Arsenic Trioxide for Structural p53 Mutations
Phase 2 Unknown
30 enrolled
Arsenic Trioxide in Treating Patients With Multiple Myeloma
Phase 2 Terminated
Arsenic Trioxide and Dexamethasone in Treating Patients With Recurrent or Refractory Stage II or Stage III Multiple Myeloma
Phase 2 Terminated
Arsenic Trioxide in Treating Patients With Myelodysplastic Syndromes
Phase 2 Terminated
Arsenic Trioxide in Treating Patients With Chronic Phase Chronic Myelogenous Leukemia That Has Not Responded to Previous Treatment
Phase 2 Withdrawn
Arsenic Trioxide in Treating Patients With Stage IV Prostate Cancer That Has Not Responded to Previous Hormone Therapy
Phase 2 Completed
37 enrolled
Arsenic Trioxide and Cholecalciferol (Vitamin D) in Treating Patients With Myelodysplastic Syndromes
Phase 2 Terminated
5 enrolled
Arsenic Trioxide in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia
Phase 2 Withdrawn
Azacitidine and Arsenic Trioxide in Treating Patients With Myelodysplastic Syndromes or Chronic Myelomonocytic Leukemia
Phase 2 Terminated
1 enrolled
Decitabine,Cytarabine and Arsenic Trioxide for Acute Myeloid Leukemia With p53 Mutations
Phase 2 Unknown
100 enrolled
Low Dose Arsenic Trioxide as a Potential Chemotherapy Protector
Phase 2 Completed
50 enrolled 7 charts
NRR
Phase 2 Terminated
3 enrolled 9 charts
Arsenic Trioxide in Treating Patients With Metastatic Liver Cancer That Cannot Be Removed by Surgery
Phase 2 Completed
25 enrolled
Transcatheter Arterial Chemoembolization (TACE) in Combination With Arsenic Trioxide Versus TACE in the Treatment of Middle-advanced Primary Hepatocellular Carcinoma (HCC) Patients
Phase 2 Unknown
190 enrolled
A Phase II Protocol of Arsenic Trioxide (Trisenox) in Subjects With Advanced Primary Carcinoma of the Liver
Phase 2 Terminated
9 enrolled 7 charts
Tretinoin and Arsenic Trioxide With or Without Idarubicin in Treating Patients With Acute Promyelocytic Leukemia
Phase 2 Terminated
1 enrolled 4 charts
Arsenic Trioxide in Treating Patients With Advanced Neuroblastoma or Other Childhood Solid Tumors
Phase 2 Completed
22 enrolled 6 charts
New Retinoid Agent Combined With Arsenic Trioxide for Untreated Acute Promyelocytic Leukemia
Phase 2 Withdrawn
Arsenic Trioxide in Treating Women With Locally Advanced or Metastatic Breast Cancer
Phase 2 Withdrawn
Liposomal Doxorubicin, Vincristine, & Dexamethasone Plus Arsenic Trioxide in Untreated Symptomatic Multiple Myeloma
Phase 2 Completed
12 enrolled
Trial of Arsenic Trioxide With Ascorbic Acid in the Treatment of Adult Non-Acute Promyelocytic Leukemia (APL) Acute Myelogenous Leukemia
Phase 2 Terminated
11 enrolled 7 charts
Arsenic Trioxide in Treating Patients With Recurrent or Refractory Acute Leukemia, Chronic Myeloide Leukemia, Myelodysplasia, Lymphoma, or Myeloma
Phase 2 Unknown
60 enrolled
Arsenic Trioxide in Treating Patients With Pancreatic Cancer That Has Not Responded to Gemcitabine
Phase 2 Completed
13 enrolled
Arsenic Trioxide, Ascorbic Acid, Dexamethasone, and Thalidomide in Treating Patients With Multiple Myeloma
Phase 2 Withdrawn
Arsenic Trioxide in Treating Men With Germ Cell Cancer
Phase 2 Completed
Arsenic Trioxide in Treating Patients With Relapsed or Refractory Chronic Myelogenous Leukemia
Phase 2 Completed
Arsenic Trioxide in Treating Patients With Stage IVB or Recurrent Cervical Cancer
Phase 2 Completed
Arsenic Trioxide in Treating Patients With Relapsed or Refractory Acute Lymphoblastic Leukemia
Phase 2 Completed
Arsenic Trioxide in Treating Patients With Relapsed or Refractory Non- Hodgkin's Lymphoma
Phase 2 Completed
Arsenic Trioxide in Treating Patients With Metastatic Kidney Cancer
Phase 2 Completed
Arsenic Trioxide in Treating Patients With Urothelial Cancer
Phase 2 Completed
35 enrolled
Arsenic Trioxide in Treating Patients With Locally Advanced or Metastatic Non-Small Cell Lung Cancer
Phase 2 Completed
30 enrolled
Arsenic Trioxide in Treating Patients With Advanced Cancer of the Esophagus or Gastroesophageal Junction
Phase 2 Terminated
50 enrolled
Chemotherapy Plus Monoclonal Antibody in Treating Patients With Acute Promyelocytic Leukemia
Phase 2 Completed
35 enrolled
Arsenic Trioxide for Induction Therapy of Adult Patients With Leukemia
Phase 2 Terminated
2 enrolled
Arsenic Trioxide in Treating Patients With Relapsed or Refractory Hodgkin's Disease
Phase 2 Terminated
2 enrolled
Arsenic Trioxide in Treating Patients With Acute Myeloid Leukemia
Phase 2 Completed
11 enrolled
Arsenic Trioxide, Thalidomide, Dexamethasone, and Ascorbic Acid in Treating Patients With Relapsed or Refractory Multiple Myeloma
Phase 2 Terminated
2 enrolled
A Phase II Study of Gleevec and Arsenic Trioxide in Patients With CML Who Fail Gleevec
Phase 2 Completed
6 enrolled
Arsenic Trioxide in Relapsed/Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma
Phase 2 Completed
41 enrolled
Treatment of Non Promyelocytic Acute Myeloid Leukaemia on Elderly Patients by Low Dose Cytosar Plus Arsenic Trioxide
Phase 2 Completed
10 enrolled